Clinical Trial Update: Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating cabozantinib-s-maleate in pediatric patients with recurrent, refractory, or newly diagnosed sarcomas, Wilms tumor, and other…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenal Cortical Carcinoma
• Alveolar Soft Part Sarcoma
• Central Nervous System Neoplasm
• Ewing Sarcoma
• Hepatoblastoma
• Hepatocellular Carcinoma
• Osteosarcoma
• Wilms Tumor

Drugs mentioned

• Cabozantinib S-Malate (cabozantinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-11-28